Literature DB >> 18328983

Osteogenesis imperfecta.

Francis H Glorieux1.   

Abstract

Osteogenesis Imperfecta is a heritable disorder characterized by bone fragility and low bone mass, with a wide spectrum of clinical expression. This review gives an update on its classification, the recent developments in the understanding of its pathophysiological mechanisms, and the current status of bisphosphonate therapy. Other therapeutic approaches and future directions of research are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18328983     DOI: 10.1016/j.berh.2007.12.012

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  39 in total

1.  Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year.

Authors:  Joanne Ruck; Noémi Dahan-Oliel; Kathleen Montpetit; Frank Rauch; François Fassier
Journal:  J Child Orthop       Date:  2011-05-08       Impact factor: 1.548

Review 2.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

Review 3.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

4.  Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.

Authors:  Kirsten Kusumi; Rose Ayoob; Sasigarn A Bowden; Susan Ingraham; John D Mahan
Journal:  J Bone Miner Metab       Date:  2014-10-16       Impact factor: 2.626

5.  Low concentrations of zoledronic acid are better at regulating bone formation and repair.

Authors:  Xiaomeng Yang; Yanqin Lu; Zhiliang Li; Yanzhou Wang; Fei Zhao; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2013-02

6.  Mutation spectrum of COL1A1/COL1A2 screening by high-resolution melting analysis of Chinese patients with osteogenesis imperfecta.

Authors:  Mingyan Ju; Xue Bai; Tianke Zhang; Yunshou Lin; Li Yang; Huaiyu Zhou; Xiaoli Chang; Shizhen Guan; Xiuzhi Ren; Keqiu Li; Yi Wang; Guang Li
Journal:  J Bone Miner Metab       Date:  2019-08-14       Impact factor: 2.626

7.  Potential implications of cell therapy for osteogenesis imperfecta.

Authors:  Christopher Niyibizi; Feng Li
Journal:  Int J Clin Rheumtol       Date:  2009-02-01

8.  Skeletal phenotypes in adult patients with osteogenesis imperfecta-correlations with COL1A1/COL1A2 genotype and collagen structure.

Authors:  J D Hald; L Folkestad; T Harsløf; A M Lund; M Duno; J B Jensen; S Neghabat; K Brixen; B Langdahl
Journal:  Osteoporos Int       Date:  2016-06-02       Impact factor: 4.507

9.  Cross-sectional and longitudinal growth patterns in osteogenesis imperfecta: implications for clinical care.

Authors:  Emily L Germain-Lee; Feng-Shu Brennen; Diana Stern; Aditi Kantipuly; Pamela Melvin; Mia S Terkowitz; Jay R Shapiro
Journal:  Pediatr Res       Date:  2015-11-05       Impact factor: 3.756

Review 10.  Connective tissue and related disorders and preterm birth: clues to genes contributing to prematurity.

Authors:  E A Anum; L D Hill; A Pandya; J F Strauss
Journal:  Placenta       Date:  2009-01-18       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.